ImmunityBio, Inc.IBRXNASDAQ
Loading
Operating Income ContractionContracting
Percentile Rank33
Studio
Year-over-Year Change

Profit from core business operations before interest and taxes

Latest
$-256.03M
↓ 14% vs avg
Percentile
P33
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-225.38M
Historical baseline
PeriodValueYoY Change
TTM$-256.03M+25.6%
2024$-344.18M+5.0%
2023$-362.25M-3.1%
2022$-351.30M-6.4%
2021$-330.28M-49.5%
2020$-220.88M-230.1%
2019$-66.91M+32.0%
2018$-98.39M+0.7%
2017$-99.12M+20.4%
2016$-124.50M-